Literature DB >> 8636129

Interaction between the insulin receptor and its downstream effectors. Use of individually expressed receptor domains for structure/function analysis.

K Paz1, H Voliovitch, Y R Hadari, C T Roberts, D LeRoith, Y Zick.   

Abstract

A structural analysis has been carried out to determine which part of the intracellular domain of the insulin receptor (IR) beta subunit is involved in direct interaction with the receptor substrates IRS-1 and Shc. Toward this end, the juxtamembrane (JM) domain (amino acids 943-984) and the carboxyl-terminal (CT) region (amino acids 1245-1 331) of IR were expressed in bacteria as (His)6-fusion peptides, and their interaction with IRS-1 and Shc was studied. We could demonstrate that the CT region of IR was sufficient to bind Shc, although significant, but much lower binding of Shc to the JM region could be detected as well. Furthermore, in vitro Tyr phosphorylation of the CT region potentiated its interactions with Shc 2-fold. In contrast, the JM region, but not the CT domain of the IR, was sufficient to mediate interactions between the IR and IRS-1. These interactions did not involve the pleckstrin homology (PH) region of IRS-1, since an IRS-1 mutant, in which four "blocks" of the PH domain (Pro5-Pro65) were deleted, interacted with the JM region of IR with the same efficiency as native IRS-1. These results suggest that the IR interacts with its downstream effectors through distinct receptor regions, and that autophosphorylation of Tyr residues located at the CT domain of the IR can modulate these interactions.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8636129     DOI: 10.1074/jbc.271.12.6998

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Trading the micro-world of combinatorial complexity for the macro-world of protein interaction domains.

Authors:  Nikolay M Borisov; Nick I Markevich; Jan B Hoek; Boris N Kholodenko
Journal:  Biosystems       Date:  2005-10-19       Impact factor: 1.973

2.  Signaling through receptors and scaffolds: independent interactions reduce combinatorial complexity.

Authors:  Nikolay M Borisov; Nick I Markevich; Jan B Hoek; Boris N Kholodenko
Journal:  Biophys J       Date:  2005-05-27       Impact factor: 4.033

Review 3.  Insulin-resistant brain state: the culprit in sporadic Alzheimer's disease?

Authors:  Sónia C Correia; Renato X Santos; George Perry; Xiongwei Zhu; Paula I Moreira; Mark A Smith
Journal:  Ageing Res Rev       Date:  2011-01-22       Impact factor: 10.895

4.  Nine-month follow-up of the insulin receptor signalling cascade in the brain of streptozotocin rat model of sporadic Alzheimer's disease.

Authors:  J Osmanovic Barilar; A Knezovic; E Grünblatt; P Riederer; M Salkovic-Petrisic
Journal:  J Neural Transm (Vienna)       Date:  2014-12-12       Impact factor: 3.575

Review 5.  HMG-CoA reductase inhibitors: do they have potential in the treatment of polycystic ovary syndrome?

Authors:  Pinar H Kodaman; Antoni J Duleba
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 6.  Statins in the treatment of polycystic ovary syndrome.

Authors:  Pinar H Kodaman; Antoni J Duleba
Journal:  Semin Reprod Med       Date:  2008-01       Impact factor: 1.303

7.  Molecular docking studies of banana flower flavonoids as insulin receptor tyrosine kinase activators as a cure for diabetes mellitus.

Authors:  Jayasree Ganugapati; Aashish Baldwa; Sarfaraz Lalani
Journal:  Bioinformation       Date:  2012-03-17

8.  Systems-level interactions between insulin-EGF networks amplify mitogenic signaling.

Authors:  Nikolay Borisov; Edita Aksamitiene; Anatoly Kiyatkin; Stefan Legewie; Jan Berkhout; Thomas Maiwald; Nikolai P Kaimachnikov; Jens Timmer; Jan B Hoek; Boris N Kholodenko
Journal:  Mol Syst Biol       Date:  2009-04-07       Impact factor: 11.429

9.  Important genetic checkpoints for insulin resistance in salt-sensitive (S) Dahl rats.

Authors:  Marlene F Shehata
Journal:  Cardiovasc Diabetol       Date:  2008-06-21       Impact factor: 9.951

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.